StreetInsider.com News Articles

Spanish Mountain Gold Drilling Intersects 103.35 Metres Grading 0.88 g/t Gold With a Higher-Grade Subset of 56.40 Metres of 1.35 g/t Gold

Tue, 03 Feb 2026 07:00:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Spanish Mountain Gold Ltd. (the "Company" or "Spanish Mountain Gold") (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF) is pleased to report additional assay results from four exploration drill holes within the Orca Fault target trend that were completed as part of its 2025 Fall Diamond Drill program (“2025 Fall Drill Program”) for the Spanish Mountain Gold (“SMG”) project, which is located in the Cariboo Gold Corridor, British Columbia, Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203389419/en/

Figure 1:
</article>
<article>
<h1>Spanish Mountain Gold Drilling Intersects 103.35 Metres Grading 0.88 g/t Gold With a Higher-Grade Subset of 56.40 Metres of 1.35 g/t Gold</h1>
<p>Tue, 03 Feb 2026 07:00:00 -0400</p>
<p> VANCOUVER, British Columbia--(BUSINESS WIRE)--
Spanish Mountain Gold Ltd. (the

Company" or "Spanish Mountain Gold") (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF) is pleased to report additional assay results from four exploration drill holes within the Orca Fault target trend that were completed as part of its 2025 Fall Diamond Drill program (“2025 Fall Drill Program”) for the Spanish Mountain Gold (“SMG”) project, which is located in the Cariboo Gold Corridor, British Columbia, Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203389419/en/

Figure 1:
</article>
<article>
<h1>Microba Announces Landmark GI Study Results From Over 4,600 Patients</h1>
<p>Wed, 14 May 2025 22:12:00 -0400</p>
<p>
<b>Results at a glance:</b>
</p><ul class=

71.4% of MetaXplore™ reports from 4,616 patients identified actionable results

41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health

9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool

19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)

65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore

BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for

Microba Announces Landmark GI Study Results From Over 4,600 Patients

Wed, 14 May 2025 22:12:00 -0400

Results at a glance:

71.4% of MetaXplore™ reports from 4,616 patients identified actionable results
41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health
9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool
19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)
65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore

Microba Announces Landmark GI Study Results From Over 4,600 Patients

Wed, 14 May 2025 22:12:00 -0400

Results at a glance:

71.4% of MetaXplore™ reports from 4,616 patients identified actionable results
41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health
9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool
19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)
65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore

Microba Announces Landmark GI Study Results From Over 4,600 Patients

Wed, 14 May 2025 22:12:00 -0400

Results at a glance:

71.4% of MetaXplore™ reports from 4,616 patients identified actionable results
41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health
9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool
19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)
65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner

Tue, 29 Apr 2025 01:52:00 -0400

Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.
These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.
Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes.

BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner

Tue, 29 Apr 2025 01:52:00 -0400

Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.
These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.
Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes.

BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome

Microba Delivers Landmark IBD Results & Signs Major Gastro Partner

Tue, 29 Apr 2025 01:52:00 -0400

Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.
These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.
Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes.

BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome